Protein tyrosine phosphatase inhibitors: a patent review and update (2012–2023)

References

• Liu H, Li X, Shi Y, et al. Protein Tyrosine Phosphatase PRL-3: a Key Player in Cancer Signaling. Biomolecules. 2024;14(3):342. doi: 10.3390/biom14030342
   PubMed Web of Science ®Google Scholar
• Roskoski R. A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacol Res. 2015;100:1–23. doi: 10.1016/j.phrs.2015.07.010
   PubMed Web of Science ®Google Scholar
• Stanford SM, Bottini N. Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders. Nat Rev Drug Discov. 2023;22(4):273–294. doi: 10.1038/s41573-022-00618-w
   PubMed Web of Science ®Google Scholar
• Wang W-Q, Sun J-P, Zhang Z-Y. An overview of the protein tyrosine phosphatase superfamily. Curr Top Med Chem. 2003;3(7):739–748. doi: 10.2174/1568026033452302
   PubMed Web of Science ®Google Scholar
• Tautz L, Critton DA, Grotegut S. Protein tyrosine phosphatases: Structure, function, and implication in human disease. Methods Mol Biol. 2013;1053:179–221.
   PubMedGoogle Scholar
• Zhang M, Liu C, Zhao L, et al. The Emerging Role of Protein Phosphatase in Regeneration. Life. 2023;13(5):1216. doi: 10.3390/life13051216
   PubMedGoogle Scholar
• Alonso A, Burkhalter S, Sasini J, et al. The minimal essential core of a cysteine-based protein-tyrosine phosphatase revealed by a novel 16-kDa VH1-like phosphatase, VHZ. J Biol Chem. 2004;279(34):35768–35774. doi: 10.1074/jbc.M403412200
   PubMed Web of Science ®Google Scholar
• Welsh CL, Pandey P, Ahuja LG. Protein Tyrosine Phosphatases: A new paradigm in an old signaling system? Adv Cancer Res. 2021;152:263–303.
   PubMed Web of Science ®Google Scholar
• Lee H, Yi JS, Lawan A, et al. Mining the function of protein tyrosine phosphatases in health and disease. Semin Cell Dev Biol. 2015;37:66–72. doi: 10.1016/j.semcdb.2014.09.021
   PubMed Web of Science ®Google Scholar
• Alonso A, Pulido R. The extended human PTPome: a growing tyrosine phosphatase family. FEBS J. 2016;283(8):1404–1429. doi: 10.1111/febs.13600
   PubMed Web of Science ®Google Scholar
• Shen R, Crean RM, Olsen KJ, et al. Insights into the importance of WPD-loop sequence for activity and structure in protein tyrosine phosphatases. Chem Sci. 2022; 13(45):13524–13540. doi: 10.1039/D2SC04135A
   PubMed Web of Science ®Google Scholar
• Torgeson KR, Clarkson MW, Granata D, et al. Conserved conformational dynamics determine enzyme activity [Internet]. Sci Adv. 2022. 8(31). Available from: https://www.science.org
   PubMed Web of Science ®Google Scholar
• Crean RM, Biler M, Van Der Kamp MW, et al. Loop dynamics and enzyme catalysis in protein tyrosine phosphatases. J Am Chem Soc. 2021;143(10):3830–3845. doi: 10.1021/jacs.0c11806
   PubMed Web of Science ®Google Scholar
• Tabernero L, Aricescu AR, Jones EY, et al. Protein tyrosine phosphatases: structure–function relationships. FEBS J. 2008;275(5):867–882. doi: 10.1111/j.1742-4658.2008.06251.x
   PubMed Web of Science ®Google Scholar
• Kolmodin K, JAÎ Q. The catalytic mechanism of protein tyrosine phosphatases revisited.
   Google Scholar
• Kozlova MI, Shalaeva DN, Dibrova DV, et al. Common mechanism of activated catalysis in P-loop fold nucleoside triphosphatases – united in diversity. Biomolecules. 2022:12
   PubMed Web of Science ®Google Scholar
• Tiganis T, Bennett AM. Protein tyrosine phosphatase function: the substrate perspective. Biochem J. 2007;402(1):1–15. doi: 10.1042/BJ20061548
   PubMedGoogle Scholar
• Yang J, Cheng Z, Niu T, et al. Structural basis for substrate specificity of protein-tyrosine phosphatase SHP-1*. J Biol Chem. 2000. Available from 275(6):4066–4071. http://www.jbc.org
   PubMed Web of Science ®Google Scholar
• Zhang Z-Y. Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development [Internet]. 2001. Available from: www.annualreviews.org
   Google Scholar
• Krishnan N, Konidaris KF, Gasser G, et al. A potent, selective, and orally bioavailable inhibitor of the protein-tyrosine phosphatase PTP1B improves insulin and leptin signaling in animal models. J Biol Chem. 2018;293(5):1517–1525. doi: 10.1074/jbc.C117.819110
   PubMed Web of Science ®Google Scholar
• Reddy Bollu L, Mazumdar A, Savage MI, et al. Molecular pathways: targeting protein tyrosine phosphatases in cancer. 2017;23(9):2136–2142. doi: 10.1158/1078-0432.ccr-16-0934
   Google Scholar
• Chen X, Keller SJ, Hafner P, et al. Tyrosine phosphatase PTPN11/SHP2 in solid tumors – bull’s eye for targeted therapy? Front Immunol. 2024;15. doi: 10.3389/fimmu.2024.1340726.
   Web of Science ®Google Scholar
• Luo R, Fu W, Shao J, et al. Discovery of a potent and selective allosteric inhibitor targeting the SHP2 tunnel site for RTK-driven cancer treatment. Eur J Med Chem. 2023;253:115305. doi: 10.1016/j.ejmech.2023
   Web of Science ®Google Scholar
• Spalinger MR, Scharl M. The role for protein tyrosine phosphatase non-receptor type 22 in regulating intestinal homeostasis. United European Gastroenterol J. 2016;4(3):325–332. doi: 10.1177/2050640615600115
   PubMed Web of Science ®Google Scholar
• Pike KA, Tremblay ML. Protein tyrosine phosphatases: regulators of CD4 T cells in inflammatory bowel disease. Front Immunol. 2018;9. doi: 10.3389/fimmu.2018.02504
   PubMed Web of Science ®Google Scholar
• He Y, Liu S, Menon A, et al. A potent and selective small-molecule inhibitor for the lymphoid-specific tyrosine phosphatase (LYP), a target associated with autoimmune diseases. J Med Chem. 2013;56(12):4990–5008. doi: 10.1021/jm400248c
   PubMed Web of Science ®Google Scholar
• Sajid A, Arora G, Singhal A, et al. Protein phosphatases of pathogenic bacteria: role in physiology and virulence. Annu Rev Microbiol. 2015;69(1):527–547. doi: 10.1146/annurev-micro-020415-111342
   PubMedGoogle Scholar
• Dhungel P, Cantu FM, Molina JA, et al. Vaccinia virus as a master of host shutoff induction: targeting processes of the central dogma and beyond. Pathogens. 2020;9(5):400. doi: 10.3390/pathogens9050400
   PubMed Web of Science ®Google Scholar
• Abdel-Magid AF. The inhibitors of protein tyrosine phosphatase nonreceptor type 2 (PTPN2) as potential enhancers of cancer immunotherapy and type 1 (PTPN1) as treatment of metabolic diseases. ACS Med Chem Lett. 2022;13(1):19–21. doi: 10.1021/acsmedchemlett.1c00678
   PubMedGoogle Scholar
• Zhang X, Jiang H, Li W, et al. Computational insight into protein tyrosine phosphatase 1B inhibition: a case study of the combined ligand- and structure-based approach. Comput Math Methods Med. 2017;2017. doi: 10.1155/2017/4245613
   Web of Science ®Google Scholar
• Shinde RN, Elizabeth Sobhia M. Geometrical criteria for characterizing open and closed states of WPD-loop in PTP1B. J Mol Struct. 2012;1017:79–83. doi: 10.1016/j.molstruc.2012.03.001
   Web of Science ®Google Scholar
• Chandrasekharappa AP, Badiger SE, Dubey PK, et al. Design and synthesis of 2-substituted benzoxazoles as novel PTP1B inhibitors. Bioorg Med Chem Lett. 2013;23(9):2579–2584. doi: 10.1016/j.bmcl.2013.02.109
   PubMed Web of Science ®Google Scholar
• Campos-Almazán MI, Hernández-Campos A, Castillo R, et al. Computational methods in cooperation with experimental approaches to design protein tyrosine phosphatase 1B inhibitors in type 2 diabetes drug design: a review of the achievements of this century. Pharmaceuticals. 2022;15(7):866. doi: 10.3390/ph15070866
   Web of Science ®Google Scholar
• Eleftheriou P, Petrou A, Geronikaki A, et al. Prediction of enzyme inhibition and mode of inhibitory action based on calculation of distances between hydrogen bond donor/acceptor groups of the molecule and docking analysis: An application on the discovery of novel effective PTP1B inhibitors. SAR QSAR Environ Res. 2015;26(7–9):557–576. doi: 10.1080/1062936X.2015.1074939
   PubMed Web of Science ®Google Scholar
• Shinde RN, Siva Kumar G, Eqbal S, et al. Screening and identification of potential PTP1B allosteric inhibitors using in silico and in vitro approaches. PLoS One. 2018;13(6):13. doi: 10.1371/journal.pone.0199020
   Web of Science ®Google Scholar
• Ma Y, Ding T-T, Liu Y-Y, et al. Design, synthesis, biological evaluation and molecular dynamics simulation studies of imidazolidine-2,4-dione derivatives as novel PTP1B inhibitors. Biochem Biophys Res Commun. 2021;579(579):40–46. doi: 10.1016/j.bbrc.2021.09.047
   PubMedGoogle Scholar
• Kostrzewa T, Jończyk J, Drzeżdżon J, et al. Synthesis, in vitro and computational studies of PTP1B phosphatase inhibitors based on oxovanadium (IV) and dioxovanadium (V) complexes. Int J Mol Sci. 2022;23(13):23. doi: 10.3390/ijms23137034
   Web of Science ®Google Scholar
• Yan F, Liu X, Zhang S, et al. Computational revelation of binding mechanisms of inhibitors to endocellular protein tyrosine phosphatase 1B using molecular dynamics simulations. J Biomol Struct Dyn. 2018;36(14):3636–3650. doi: 10.1080/07391102.2017.1394221
   PubMed Web of Science ®Google Scholar
• Hou X, Rooklin D, Yang D, et al. Computational strategy for bound state structure prediction in structure-based virtual screening: a case study of protein tyrosine phosphatase receptor type O inhibitors. J Chem Inf Model. 2018;58(11):2331–2342. doi: 10.1021/acs.jcim.8b00548
   PubMed Web of Science ®Google Scholar
• Mullard A. Phosphatases start shedding their stigma of undruggability. Nat Rev Drug Discov. 2018;17(12):847–849. doi: 10.1038/nrd.2018.201
   PubMed Web of Science ®Google Scholar
• Shi D, Li J, Han L, et al. Institute of oceanology, chinese academy of sciences chemical synthesis method of bromphenol PTP1B inhibitor. CN101597213 2012
   Google Scholar
• Shi D, Fan X, Cui Y, et al. Institute of oceanology, chinese academy of sciences. three protein tyrosine phosphatase 1B (PTP1B) inhibitors and synthesis and application there of. CN102020540. 2012.
   Google Scholar
• Shi D, Guo S, Fan X, et al. Institute of oceanology, chinese academy of sciences. PTP1B inhibitors, synthesis thereof and application thereof in preparation of medicament for treating type 2 diabetes mellitus. 2013:p. US2013131182.
   Google Scholar
• Chen X, Fengxia H, Chenyu Z, et al. University of Nanjing. Suppressive activity of mango aglycone on PTP1B and application thereof. CN101669934. 2013.
   Google Scholar
• McLane M, Ruiz-White I, Maloy WL, et al. Pharmaceutical, Inc. Aminosteroide for the treatment of a PTP1B associated disease. 2013:p. WO2013158970.
   Google Scholar
• Foshan Saiweisi Pharmaceutical Technology Co Ltd. PTP (protein tyrosine phosphatase) 1B inhibitors containing tetrazole structure as well as preparation methods and application of PTP1B inhibitors. CN104803931A. 2015.
   Google Scholar
• Foshan Saiweisi Pharmaceutical Technology Co Ltd. Salts of pyridazino[2,3-a]pyrrolo[2,1-c]quinoxaline for the treatment of leishmania infections and diseases that involve the protein tyrosine phosphatase 1b. WO2015004304A1; 2015.
   Google Scholar
• La Jolla Institute of Allergy and Immunology; Stanford Burnham Prebys Medical Discovery Institute. Inhibitor of low molecular weight protein tyrosine phosphatase and application thereof. 2016. CN107427506A.
   Google Scholar
• Shanxi University. Metal copper complexes of serine N derivant and its preparation method and application. CN104829635B; 2016.
   Google Scholar
• Qilu University of Technology. New Type Urea albuminoid tyrosine-phosphatase 1B inhibitor and preparation method thereof, pharmaceutical composition and purposes. CN106167456A;2016.
   Google Scholar
• Central South University of Forestry & Technology. A kind of application of sesquiterpenoids natural small molecule compounds in inhibitors of protein tyrosine phosphatase is prepared. CN107468675A. 2017.
   Google Scholar
• Shanxi University. A kind of application of sesquiterpenoids natural small molecule compounds in inhibitors of protein tyrosine phosphatase is prepared. CN106432308A. 2017.
   Google Scholar
• University of Jinan. A kind of 1,2,4 oxadiazole derivatives, preparation method and its medical usage. CN106977504A; 2017.
   Google Scholar
• Otsuka Pharmaceutical Co Ltd, Therapeutic compounds and related methods of use, US9630947B2. 2017.
   Google Scholar
• Fudan University. Phloroglucinol abietane diterpenoid compound, preparation method thereof and medicinal application. CN105837592A; 2018.
   Google Scholar
• Indiana University Research and Technology Corp. Hydroxyindole carboxylic acid based inhibitors for oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (shp2). EP2988741B1. 2019.
   Google Scholar
• Yanbian University. A kind of PTP1B inhibitor of the structure of rhodanine containing indolepopionic acid and its preparation and application. CN110078724A; 2019.
   Google Scholar
• Sanford Burnham Prebys Medical Discovery Institute. Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof. WO2019136093A1; 2019.
   Google Scholar
• Anhui Polytechnic University. Salvia root P.E is preparing protein-tyrosine phosphatase 1B inhibitor and prevention and/or is treating the application in diabetes B drug. CN109820889A; 2019.
   Google Scholar
• Nantong University. A kind of containing 5 phenyl isoxazole class compounds and preparation method thereof. CN106117156A; 2019.
   Google Scholar
• Nankai University. Protein tyrosine phosphatase 2 receptor antagonist and application thereof. CN110818769A; 2020.
   Google Scholar
• Korea Inst. Ocean Sci. & Tech. Protein tyrosine phosphatase 1b inhibitor from Antarctic marine-derived aspergillus sp. sf-5929. WO2020017864A1; 2020.
   Google Scholar
• La Jolla Institute for Allergy and Immunology, Sanford Burnham Prebys Medical Discovery Institute. Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof. WO2021/003398A1;2021.
   Google Scholar
• Johns Hopkins University. Targeting ptpn22 in cancer therapy, WO2021007491A1. 2021.
   Google Scholar
• Calico Life Sciences Llc, Abbvie Inc. Protein tyrosine phosphatase targeting ligands, WO2023019166A1. 2022.
   Google Scholar
• University of Texas System, Heterocyclic inhibitors of PTPN11. US11466017B2;2022.
   Google Scholar
• Nerio Therapeutics. Protein tyrosine phosphatase inhibitors and uses thereof, WO2023150150A1. 2023.
   Google Scholar
• Bristol-Myers Squibb Company. Inhibitors of protein tyrosine phosphatase, compositions, and methods of use. WO2023147531A1. 2023.
   Google Scholar
• Shi D, Li J, Han L, et al. Institute of Oceanology, Chinese Academy of Sciences. PTP1B inhibitor as well as synthesis method and application thereof in preparation of medicine for curing type 2 diabetes. CN101597217. 2012.
   Google Scholar
• Shi D, Fan X, Li J, et al. Institute of Oceanology, Chinese Academy of Sciences. Protein tyrosine phosphatase 1B (PTP1B) inhibitor, and synthesis and application thereof. CN102020537; 2014.
   Google Scholar
• Shi D, Fan X, Li J, et al. Institute of Oceanology, Chinese Academy of Sciences. PTP1B (Protein Tyrosine Phosphatase 1B) inhibitor as well as synthesis method and application thereof to preparation of type 2 diabetes medicament. CN102020538; 2012.
   Google Scholar
• Shi D, Fan X, Li J, et al. Institute of Oceanology, Chinese Academy of Sciences. PTP1B (Protein Tyrosine Phosphatase 1B) inhibitor, synthesis and application thereof in preparation of drugs for treating type 2 diabetes mellitus. CN102020539. 2012.
   Google Scholar
• Gray JL, Amarasinghe KKD, Clark CM, et al. Human protein tyrosine phosphatase inhibitors and methods of Use. US Patent US20130023543A1, filed 2012 Sep 25, and issued. 2013 [2013 Jan 24.
   Google Scholar
• Foshan Saiweisi Pharmaceutical Technology Co Ltd. PTP1B (protein tyrosine phosphatase 1B) inhibitors with thiazolecarbonitrile and cyclopentadiene structures and application of inhibitors. CN104803946A. 2015.
   Google Scholar
• Qilu University of Technology. N-{4-[3-(3,4 dimethoxy-phenyl)-ureidomethyl]-2,5-diethoxy-phenyl}-methanesulfonamide new compound and preparation method and application thereof. CN105820075A. 2016.
   Google Scholar
• Yale University, Compositions and methods for inhibiting ptpn22, WO2017205765A1. 2017.
   Google Scholar
• Institute of Oceanology of CAS. Novel fluorinated PTP1B (protein tyrosine phosphatase 1B) inhibitor as well as synthesis method and application thereof. CN105777505A; 2018.
   Google Scholar
• Taizhou University. Application of triterpenes and dimer compounds thereof in preparation of medicines for treating diseases mediated by protein tyrosine phosphatase 1B. CN113425730A; 2021.
   Google Scholar
• Wuhan vocational college of software and engineering, Wuhan Open University. Application of compound in preparation of PTP1B inhibitor and pharmaceutical composition thereof. CN117143937A. 2023.
   Google Scholar
• Zhang ZY. Drugging the undruggable: therapeutic potential of targeting protein tyrosine phosphatases. Acc Chem Res. 2017;50:122–129. doi: 10.1021/acs.accounts.6b00537
   PubMed Web of Science ®Google Scholar